Oncolytics Biotech (NASDAQ:ONCY) Director Bernd Seizinger Buys 40,000 Shares of Stock

Oncolytics Biotech Inc. (NASDAQ:ONCY) Director Bernd Seizinger purchased 40,000 shares of the company’s stock in a transaction that occurred on Thursday, February 12th. The stock was acquired at an average cost of $0.85 per share, for a total transaction of $34,000.00. Following the transaction, the director owned 566,991 shares in the company, valued at $481,942.35. This represents a 7.59% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Oncolytics Biotech Stock Performance

Shares of ONCY stock opened at $1.06 on Friday. The company has a market capitalization of $112.52 million, a price-to-earnings ratio of -3.79 and a beta of 0.99. Oncolytics Biotech Inc. has a 52-week low of $0.33 and a 52-week high of $1.51. The company has a 50-day simple moving average of $0.98 and a two-hundred day simple moving average of $1.07.

Oncolytics Biotech (NASDAQ:ONCY) last released its earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. On average, sell-side analysts forecast that Oncolytics Biotech Inc. will post -0.28 EPS for the current fiscal year.

Trending Headlines about Oncolytics Biotech

Here are the key news stories impacting Oncolytics Biotech this week:

• Positive Sentiment: Director Patricia S. Andrews bought 35,400 shares at $0.86 (raising her stake 82.85% to 78,128 shares). SEC Filing
• Positive Sentiment: Insider Andrew Aromando purchased 29,600 shares at $0.86 (increasing his position 116.08% to 55,100 shares). SEC Filing
• Positive Sentiment: Director Bernd R. Seizinger acquired a total of 100,000 shares across Feb. 11–12 (60k at $0.83 and 40k at $0.85), boosting his holdings to ~566,991 shares. SEC Filing
• Positive Sentiment: VP Allison Hagerman bought 10,000 shares at $0.83 (raising her stake ~9.5% to 115,059 shares). SEC Filing
• Positive Sentiment: Director Deborah M. Brown purchased 25,000 shares at $0.85 (a ~29.5% increase; now ~109,851 shares). SEC Filing
• Positive Sentiment: Insider Thomas C. Heineman bought 12,132 shares at $0.83 (increasing to ~282,818 shares). SEC Filing
• Positive Sentiment: Director Wayne Pisano purchased 30,000 shares at $0.84 (raising his stake ~6.5% to ~492,414 shares). SEC Filing
• Positive Sentiment: CFO Kirk Look bought 12,000 shares at $0.84 (increasing to ~287,515 shares). SEC Filing
• Positive Sentiment: CEO Jared Kelly purchased a total of 35,100 shares across Feb. 11–12 at ~$0.84 (bringing his holdings to ~109,000 shares, a ~37% increase). SEC Filing

Analysts Set New Price Targets

ONCY has been the subject of several research reports. HC Wainwright increased their price target on Oncolytics Biotech from $5.00 to $10.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Oncolytics Biotech in a report on Monday, December 29th. Wall Street Zen lowered shares of Oncolytics Biotech from a “hold” rating to a “sell” rating in a research note on Saturday, November 15th. Finally, Zacks Research raised shares of Oncolytics Biotech from a “hold” rating to a “strong-buy” rating in a report on Friday, October 17th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $6.25.

Hedge Funds Weigh In On Oncolytics Biotech

Institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC bought a new stake in shares of Oncolytics Biotech during the 3rd quarter valued at about $535,000. Tocqueville Asset Management L.P. bought a new stake in Oncolytics Biotech during the fourth quarter valued at approximately $63,000. CIBC Private Wealth Group LLC purchased a new position in Oncolytics Biotech in the 4th quarter worth approximately $44,000. Ground Swell Capital LLC purchased a new position in Oncolytics Biotech in the 4th quarter worth approximately $30,000. Finally, Seeds Investor LLC increased its holdings in shares of Oncolytics Biotech by 17.8% in the 2nd quarter. Seeds Investor LLC now owns 223,767 shares of the company’s stock worth $173,000 after buying an additional 33,826 shares during the last quarter. 6.82% of the stock is currently owned by institutional investors.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors.

Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers.